Rachela Popovtzer

Prof. Rachela Popovtzer


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2017 in ACS Nano
Verified
Journal Article
Closed access
OBOshra Betzer
Oshra Betzer
NPNisim Perets
Nisim Perets
AAAriel Angel
Ariel Angel
MMMenachem Motiei
Menachem Motiei
TSTamar Sadan
Tamar Sadan
RPRachela Popovtzer
Rachela Popovtzer

27 August 2019 in ACS Nano
Verified
Journal Article
Closed access
SGShaowei Guo
Shaowei Guo
NPNisim Perets
Nisim Perets
OBOshra Betzer
Oshra Betzer
SBShahar Ben-Shaul
Shahar Ben-Shaul
ASAnton Sheinin
Anton Sheinin
SLShulamit Levenberg
Shulamit Levenberg

14 February 2019 in Nano Letters
Verified
Journal Article
Closed access
NPNisim Perets
Nisim Perets
OBOshra Betzer
Oshra Betzer
RSRonit Shapira
Ronit Shapira
SBShmuel Brenstein
Shmuel Brenstein
AAAriel Angel
Ariel Angel
DODaniel Offen
Daniel Offen

16 June 2017 in Nanomedicine
Verified
Journal Article
Closed access
OBOshra Betzer
Oshra Betzer
MSMalka Shilo
Malka Shilo
RORenana Opochinsky
Renana Opochinsky
EBEran Barnoy
Eran Barnoy
MMMenachem Motiei
Menachem Motiei
RPRachela Popovtzer
Rachela Popovtzer
Aim: Our goal was to develop an efficient nanoparticle-based system that can overcome the restrictive mechanism of the blood–brain barrier (BBB) by targeting insulin receptors and would thus enable drug delivery to the brain. Methods: Insulin-coated gold nanoparticles (INS-GNPs) were synthesized to serve as a BBB transport system. The effect of nanoparticle size (20, 50 and 70 nm) on their ability to cross the BBB was quantitatively investigated in Balb/C mice. Results: The most widespread biodistribution and highest accumulation within the brain were observed using 20 nm INS-GNPs, 2 h post injection. In vivo CT imaging revealed that particles migrated to specific brain regions, which are involved in neurodegenerative and neuropsychiatric disorders. Conclusion: These findings promote the optimization of nanovehicles for transport of drugs through the BBB. The insulin coating of the particles enabled targeting of specific brain regions, suggesting the potential use of INS-GNPs for delivery of various treat...

11 June 2015 in ACS Nano
Verified
Journal Article
Closed access
RMRinat Meir
Rinat Meir
KSKaterina Shamalov
Katerina Shamalov
OBOshra Betzer
Oshra Betzer
MMMenachem Motiei
Menachem Motiei
MHMiryam Horovitz-Fried
Miryam Horovitz-Fried
CCCyrille J. Cohen
Cyrille J. Cohen

4 March 2015 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
MSMalka Shilo
Malka Shilo
ASAnat Sharon
Anat Sharon
KBKoby Baranes
Koby Baranes
MMMenachem Motiei
Menachem Motiei
JLJean-Paul Lellouche
Jean-Paul Lellouche
RPRachela Popovtzer
Rachela Popovtzer
During the last decade nanoparticles have gained attention as promising drug delivery agents that can transport through the blood brain barrier. Recently, several studies have demonstrated that specifically targeted nanoparticles which carry a large payload of therapeutic agents can effectively enhance therapeutic agent delivery to the brain. However, it is difficult to draw definite design principles across these studies, owing to the differences in material, size, shape and targeting agents of the nanoparticles. Therefore, the main objective of this study is to develop general design principles that link the size of the nanoparticle with the probability to cross the blood brain barrier. Specifically, we investigate the effect of the nanoparticle size on the probability of barbiturate coated GNPs to cross the blood brain barrier by using bEnd.3 brain endothelial cells as an in vitro blood brain barrier model. The results show that GNPs of size 70 nm are optimal for the maximum amount of gold within the brain cells, and that 20 nm GNPs are the optimal size for maximum free surface area. These findings can help understand the effect of particle size on the ability to cross the blood brain barrier through the endothelial cell model, and design nanoparticles for brain imaging/therapy contrast agents.